United-Guardian, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017, compared with FY2016. This is an annual report; it does not provide standalone fourth-quarter results.
Business context
The company manufactures and markets personal care and cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It reports as one business segment. LUBRAJEL and RENACIDIN together accounted for approximately 94% of 2017 sales. Its largest marketing partner, Ashland Specialty Ingredients (ASI), represented approximately 40% of total sales.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Gross sales | $13.43 million | $11.14 million |
| Net sales | $12.97 million | $10.78 million |
| Gross profit margin | Approximately 59% | Approximately 55% |
| Income from operations | $5.24 million | $3.39 million |
| Net income | $3.84 million | $2.58 million |
| Basic and diluted EPS | $0.84 | $0.56 |
| Cash from operations | $3.99 million | $2.29 million |
Gross sales rose about 21%; net income increased about 49%. Higher sales of personal care products and pharmaceuticals drove growth, while improved gross margin primarily reflected a greater share of higher-margin LUBRAJEL sales. Operating expenses declined modestly to $1.79 million. The effective tax rate was 30.7%, versus 30.2% in 2016.
At year-end, cash and cash equivalents were $725,000 and marketable securities were $7.72 million. Working capital was $10.43 million, down 18% year over year; the current ratio fell to 8.3 from 13.1, mainly due to lower marketable securities and higher accounts payable. The company reported no material capital expenditure commitments and management considered working capital sufficient for the next fiscal year. No interest-bearing debt is shown in the provided balance sheet.
Investing activities provided $2.82 million, mainly reflecting proceeds from marketable securities; financing activities used $6.51 million, primarily for dividends. The company paid $0.42 per share in the first half and $1.00 per share, including a special dividend, in the second half. FY2017 dividends paid totaled $6.51 million.
Material changes and operating developments
- Personal care sales increased approximately 40% to $6.87 million, chiefly because ASI resumed and increased LUBRAJEL OIL sales for China after a prior regulatory-related disruption and inventory overhang.
- Pharmaceutical sales increased approximately 16% to about $3.99 million. RENACIDIN sales rose approximately 18%, supported by the 30 mL single-dose format introduced in 2016.
- Medical product sales fell approximately 8% to $2.42 million, largely because of lower LUBRAJEL RR purchases following customer overstocking in 2016 and variable ordering patterns.
- Research and development spending was $646,079, roughly level with 2016. Management expected 2018 R&D spending to be comparable.
- Accounts receivable rose 19% to $1.91 million; days sales outstanding increased to 49 from 42.
Outlook, risks, and unusual items
Management expressed optimism about continued RENACIDIN growth and sales development for newer natural-ingredient products, but provided no quantitative revenue or earnings guidance. Several development projects remain at early stages, and the company cautioned that they may not become marketable or generate significant sales. Management anticipated sampling LUBRAJEL OIL NATURAL with a view to possible marketing in 2018 and expected natural-preservative-booster revenue, if successful, no earlier than 2019.
Key risks include pricing pressure and lower-cost competitors, particularly in China; dependence on marketing partners and concentrated customers; variable customer ordering and inventory patterns; and regulatory requirements affecting pharmaceutical products. ASI’s purchases are recorded as domestic sales because shipments go to U.S. warehouses, although ASI reported that 72% of its sales of the company’s products went to foreign customers and that China accounted for 55% of those sales. Six raw-material vendors represented 88% of raw-material purchases.
The company adopted the new revenue recognition standard effective January 1, 2018 and expected no material financial-statement impact. The 2017 financial statements reflect a $34,595 reclassification related to the federal tax-rate change. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not issue an internal-control attestation. The filing reports no legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether ASI’s China demand and orders remain steady, and how much the company’s results depend on this partner and market.
- Whether the improved sales mix and gross margin are sustainable amid competitive pricing pressure.
- RENACIDIN sales trends, including whether the single-dose format continues to drive growth and how related rebates, returns, and distribution allowances evolve.
- Customer concentration and collections: the filing says two distributors/marketing partners accounted for approximately 55% of sales and 58% of year-end receivables; review the detailed customer disclosures.
- Dividend sustainability relative to operating cash flow, given FY2017 dividends paid exceeded cash generated from operations.